Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses survival data from this clinical trial on pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma. (Abstract 1107O) Follow him on Twitter: @omidhamidmd
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses in French phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)
Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)
Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)
